Note: All changes are versus the prior-year period unless otherwise stated
Astellas stated that revenues for Xtandi, Xospata, Padcev and Evrenzo "increased as expected" during the first quarter. Other factors that bolstered the company's performance include sales growth for Betanis/Myrbetriq/Betmiga to treat overactive bladder, plus Lexiscan revenues returning to pre-pandemic levels. The company said these gains were offset mainly due to the termination of sales promotion activities for the anti-inflammatory Celecox, the transfer of manufacturing rights of Lipitor, and the divestiture of Eligard for the treatment of prostate cancer.
Astellas is maintaining its full fiscal-year forecast of sales totaling JPY 1.3 trillion ($11.8 billion), but lowering its profit outlook to JPY 183 billion ($1.7 billion) from an estimate of JPY 209 billion ($1.9 billion) previously.
The Japanese drugmaker said the downward profit revision took into account impairment losses related to the termination of development projects for the DNA vaccine ASP0892, which was in Phase I development for peanut allergy, and the anti-CD40 monoclonal antibody bleselumab, which was in Phase II for recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients.
To read more Top Story articles, click here.